B08: A THIRD BNT162B2 DOSE INDUCES ANTIBODY RESPONSES AGAINST SARS-COV-2 EVEN IN PREVIOUSLY NON-RESPONDERS WITH MULTIPLE MYELOMA

por Terpos, E, Gavriatopoulou, M, Ntanasis-Stathopoulos, I, Briasoulis, A, Gumeni, S, Malandrakis, P, Papanagnou, E-D, Migkou, M, Kanellias, N, Kastritis, E, Trougakos, I P, Dimopoulos, M A
Publicado 2022

P54 ORAL ANTIVIRALS RITONAVIR-NIRMATRELVIR AND MOLNUPIRAVIR ARE HIGHLY EFFECTIVE IN PATIENTS WITH MULTIPLE MYELOMA AND COVID-19; A SINGLE-CENTER, PROSPECTIVE STUDY

por Spiliopoulou, V., Ntanasis-Stathopoulos, I., Malandrakis, P., Gavriatopoulou, M., Theodorakakou, F., Fotiou, D., Syrigou, R. E., Migkou, M., Roussou, M., Eleutherakis-Papaiakovou, E., Kastritis, E., Dimopoulos, M. A, Terpos, E.
Publicado 2023

P57 PRE-EXPOSURE PROPHYLAXIS FOR COVID-19 WITH TIXAGEVIMAB/CILGAVIMAB (EVUSHELD) IN PATIENTS WITH MULTIPLE MYELOMA

por Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Eleutherakis-Papaiakovou, E., Malandrakis, P., Spiliopoulou, V., Syrigou, R.E., Theodorakakou, F., Fotiou, D., Migkou, M., Roussou, M., Kastritis, E., Dimopoulos, M.A., Terpos, E.
Publicado 2023

P14 OCULAR TOXICITY IN TRANSPLANT INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN, LENALIDOMIDE AND DEXAMETHASONE IN A PHASE 1/2 TRIAL

por Ntanasis-Stathopoulos, I., Gavriatopoulou, M., Malandrakis, P., Fotiou, D., Kanellias, N., Migkou, M., Theodorakakou, F., Spiliopoulou, V., Syrigou, R., Eleutherakis-Papaiakovou, E., Gkolfinopoulos, S., Manousou, K., Kastritis, E., Dimopoulos, M.A., Terpos, E.
Publicado 2023

P16: DARATUMUMAB MONOTHERAPY HAS A FAVORABLE EFFECT ON BONE METABOLISM IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA; RESULTS OF THE PHASE 2 REBUILD STUDY

por Terpos, E, Ntanasis-Stathopoulos, I, Kastritis, E, Hatjiharissi, E, Katodritou, E, Eleutherakis-Papaiakovou, E, Verrou, E, Gavriatopoulou, M, Leonidakis, A, Delimpasi, S, Malandrakis, P, Kyrtsonis, M-C, Papaioannou, M, Symeonidis, A, Dimopoulos, MA
Publicado 2022

B06 HIGH LEVELS OF CIRCULATING PLASMA CELLS AT DIAGNOSIS ARE PREDICTIVE FOR WORSE PROGNOSIS IN BOTH TRANSPLANT-ELIGIBLE AND -INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA

por Malandrakis, P., Ntanasis-Stathopoulos, I., Kostopoulos, I.V., Roussakis, P., Eleutherakis-Papaiakovou, E., Panteli, C., Angelis, N., Spiliopoulou, V., Orologas-Stavrou, N., Theodorakakou, F., Fotiou, D., Migkou, M., Gavriatopoulou, M., Kastritis, E., Tsitsilonis, O.E., Dimopoulos, M.A., Terpos, E.
Publicado 2023